New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
07:09 EDTCCXIChemoCentryx announces Phase I clinical trial for CCX972 in France
ChemoCentryx announced the initiation of a Phase I clinical trial for CCX872, the company's next-generation of orally administered inhibitors targeting the chemokine receptor known as CCR2. The double-blind, placebo-controlled, single and multiple ascending dose study will evaluate the safety, tolerability and pharmacokinetics of CCX872 in 40 healthy adult subjects. ChemoCentryx' CCR2 program also includes CCX140, the Company's lead CCR2 inhibitor, currently in Phase II clinical trials for the treatment of diabetic nephropathy.
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2015
07:56 EDTCCXIChemoCentryx pancreatic cancer data could drive upside, says JPMorgan
JPMorgan analyst Anupam Rama says ChemoCentryx (CCXI) should report before year-end initial data from the Phase 1b trial of CCX872 in pancreatic cancer. Prior data with competitor CCR2 inhibitor PF-04136309 from Pfizer (PFE) support proof-of-concept in the indication, Rama tells investors in a research note. Further, physician feedback indicates Chemocentyx's proposed benchmark for the program is appropriate, the analyst adds. Rama views ChemoCentryx as undervalued and under-followed and sees CCX872 as "relatively underappreciated." The analyst thinks the Phase 1b data could be an "upside lever" and reiterates an Overweight rating on ChemoCentryx with a $14 price target.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use